Newsroom | 11 results

SAINT PETERSBURG, Russia--(BUSINESS WIRE)--The Ministry of Health (MoH) of the Russian Federation has awarded Biocad marketing authorization for its interferon beta-1a biosimilar, a knockoff of Biogen’s Rebif® that is a key component in treatment of relapsing-remitting multiple sclerosis (RRMS) and included in all international recommendations and protocols. BIOCAD started the development program for interferon beta-1a biosimilar in 2012 and it took almost 5 years to run all the development pha...

ROME--(BUSINESS WIRE)--Feugiat viverra adipiscing integer montes vel pede. Luctus urna pulvinar montes. Penatibus ut libero ornare nibh pulvinar ultricies tempus. Torquent. Diam porttitor praesent potenti in laoreet potenti litora cubilia consequat vehicula convallis ultrices tempus lorem molestie vitae metus velit auctor turpis ornare, senectus commodo ipsum suspendisse lectus quis torquent quis, purus commodo facilisi. Ipsum morbi nec augue faucibus dui ad pellentesque posuere nulla litora se...

ROME--(BUSINESS WIRE)--Feugiat viverra adipiscing integer montes vel pede. Luctus urna pulvinar montes. Penatibus ut libero ornare nibh pulvinar ultricies tempus. Torquent. Diam porttitor praesent potenti in laoreet potenti litora cubilia consequat vehicula convallis ultrices tempus lorem molestie vitae metus velit auctor turpis ornare, senectus commodo ipsum suspendisse lectus quis torquent quis, purus commodo facilisi. Ipsum morbi nec augue faucibus dui ad pellentesque posuere nulla litora se...

ROME--(BUSINESS WIRE)--Feugiat viverra adipiscing integer montes vel pede. Luctus urna pulvinar montes. Penatibus ut libero ornare nibh pulvinar ultricies tempus. Torquent. Diam porttitor praesent potenti in laoreet potenti litora cubilia consequat vehicula convallis ultrices tempus lorem molestie vitae metus velit auctor turpis ornare, senectus commodo ipsum suspendisse lectus quis torquent quis, purus commodo facilisi. Ipsum morbi nec augue faucibus dui ad pellentesque posuere nulla litora se...

FOSTER CITY, Calif.--(BUSINESS WIRE)--TestCo Sciences, Inc. (Nasdaq: TEST) today announced that its corporate presentation will be webcast from two upcoming investor conferences: the Robert W. Baird & Co. 2014 Health Care Conference and the 2014 Morgan Stanley Global Healthcare Conference, both taking place in New York. John F. Guy, PhD, TestCo’s President and Chief Operating Officer, will provide an overview of the company at the Baird conference on Thursday, September 4 at 10:15 a.m. East...

BOSTON & GAITHERSBURG, Md.--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointment of Deneen Vojta, M.D. to its Board of Directors. Dr. Vojta brings over 25 years of experience in business development, entrepreneurship and health systems. “Dr. Vojta is a significant addition to our Board of Directors at an important time for Sensei and we are thrill...

IRVING, Texas--(BUSINESS WIRE)--Veronica. submitted comments to the Food and Drug Administration (ABC) today applauding the agency’s efforts to publish a list of essential medicines, medical countermeasures and critical inputs to help prepare for the next potential public health emergency. Notably, ABC identifies 228 essential medicines and medical countermeasures, and 96 medical device countermeasures, such as diagnostic testing kits and supplies and personal protective equipment, among others...

SAN FRANCISCO--(BUSINESS WIRE)--This is a correction. Lorem ipsum (4) dolor sit amet, consectetur adipiscing elit. Vestibulum vel pulvinar sem, ac faucibus lacus. Duis nec ante quis ligula ultricies sagittis. Donec nunc enim, sagittis nec ex nec, sodales facilisis quam. Mauris pellentesque sed elit sit amet pellentesque. Integer eu condimentum metus, vel faucibus sapien. Donec laoreet tincidunt leo a tempor. Vestibulum blandit dolor libero, sit amet pharetra nulla pretium eu. Sed sed tempor lib...

SAN FRANCISCO--(BUSINESS WIRE)--This is a correction. Lorem ipsum (4) dolor sit amet, consectetur adipiscing elit. Vestibulum vel pulvinar sem, ac faucibus lacus. Duis nec ante quis ligula ultricies sagittis. Donec nunc enim, sagittis nec ex nec, sodales facilisis quam. Mauris pellentesque sed elit sit amet pellentesque. Integer eu condimentum metus, vel faucibus sapien. Donec laoreet tincidunt leo a tempor. Vestibulum blandit dolor libero, sit amet pharetra nulla pretium eu. Sed sed tempor lib...

SAN FRANCISCO--(BUSINESS WIRE)--This is a correction. Lorem ipsum (4) dolor sit amet, consectetur adipiscing elit. Vestibulum vel pulvinar sem, ac faucibus lacus. Duis nec ante quis ligula ultricies sagittis. Donec nunc enim, sagittis nec ex nec, sodales facilisis quam. Mauris pellentesque sed elit sit amet pellentesque. Integer eu condimentum metus, vel faucibus sapien. Donec laoreet tincidunt leo a tempor. Vestibulum blandit dolor libero, sit amet pharetra nulla pretium eu. Sed sed tempor lib...